BACKGROUND & AIMS: The incidence of esophageal and gastric cardia adenocarcinoma has increased in Western countries in recent decades for largely unknown reasons. We investigated whether use of LES-relaxing drugs was related to an increased risk of esophageal and gastric cardia adenocarcinoma, and whether use of NSAIDs was related to a reduced risk of esophageal and gastric cancers. METHODS: We examined these associations by using administrative databases in a case-control study in 2 integrated health care delivery systems. Cases were incident esophageal adenocarcinomas (n = 163) and squamous cell carcinomas (n = 114) and gastric cardia (n = 176) and non-cardia adenocarcinomas (n = 320), diagnosed between 1980-2002 in one health system and between 1993-2002 in the other. Matched controls (n = 3996) were selected. Complete prescription information was available for the study period. RESULTS: Prescription of corticosteroids was associated with a decreased risk of esophageal adenocarcinoma (odds ratio [OR], 0.6; 95% confidence interval [CI], 0.4-0.9), esophageal squamous cell carcinoma (OR, 0.4; 95% CI, 0.2-0.6), and gastric non-cardia carcinoma (OR, 0.4, 95% CI, 0.3-0.6). Ever use of pharmacy-purchased aspirin was associated with 30%-60% decreased risks of the studied cancers. As a group, LES-relaxing drugs showed little evidence of association with increased risk of any esophageal or gastric cancer. CONCLUSIONS: Corticosteroid and aspirin use were associated with significantly decreased risks of esophageal and gastric cancer. LES-relaxing drugs as a group did not affect these risks, although we had limited power to assess individual drugs. The possibility that corticosteroids and aspirin might reduce esophageal cancer risk warrants further consideration.
BACKGROUND & AIMS: The incidence of esophageal and gastric cardia adenocarcinoma has increased in Western countries in recent decades for largely unknown reasons. We investigated whether use of LES-relaxing drugs was related to an increased risk of esophageal and gastric cardia adenocarcinoma, and whether use of NSAIDs was related to a reduced risk of esophageal and gastric cancers. METHODS: We examined these associations by using administrative databases in a case-control study in 2 integrated health care delivery systems. Cases were incident esophageal adenocarcinomas (n = 163) and squamous cell carcinomas (n = 114) and gastric cardia (n = 176) and non-cardia adenocarcinomas (n = 320), diagnosed between 1980-2002 in one health system and between 1993-2002 in the other. Matched controls (n = 3996) were selected. Complete prescription information was available for the study period. RESULTS: Prescription of corticosteroids was associated with a decreased risk of esophageal adenocarcinoma (odds ratio [OR], 0.6; 95% confidence interval [CI], 0.4-0.9), esophageal squamous cell carcinoma (OR, 0.4; 95% CI, 0.2-0.6), and gastric non-cardia carcinoma (OR, 0.4, 95% CI, 0.3-0.6). Ever use of pharmacy-purchased aspirin was associated with 30%-60% decreased risks of the studied cancers. As a group, LES-relaxing drugs showed little evidence of association with increased risk of any esophageal or gastric cancer. CONCLUSIONS: Corticosteroid and aspirin use were associated with significantly decreased risks of esophageal and gastric cancer. LES-relaxing drugs as a group did not affect these risks, although we had limited power to assess individual drugs. The possibility that corticosteroids and aspirin might reduce esophageal cancer risk warrants further consideration.
Authors: Thomas L Vaughan; Linda M Dong; Patricia L Blount; Kamran Ayub; Robert D Odze; Carissa A Sanchez; Peter S Rabinovitch; Brian J Reid Journal: Lancet Oncol Date: 2005-12 Impact factor: 41.316
Authors: Paul J Limburg; Wenqiang Wei; Dennis J Ahnen; Youlin Qiao; Ernest T Hawk; Guoqing Wang; Carol A Giffen; Guiqi Wang; Mark J Roth; Ning Lu; Edward L Korn; Yurong Ma; Kathleen L Caldwell; Zheiwei Dong; Philip R Taylor; Sanford M Dawsey Journal: Gastroenterology Date: 2005-09 Impact factor: 22.682
Authors: Edward H Wagner; Sarah M Greene; Gene Hart; Terry S Field; Suzanne Fletcher; Ann M Geiger; Lisa J Herrinton; Mark C Hornbrook; Christine C Johnson; Judy Mouchawar; Sharon J Rolnick; Victor J Stevens; Stephen H Taplin; Dennis Tolsma; Thomas M Vogt Journal: J Natl Cancer Inst Monogr Date: 2005
Authors: D C Farrow; T L Vaughan; C Sweeney; M D Gammon; W H Chow; H A Risch; J L Stanford; P D Hansten; S T Mayne; J B Schoenberg; H Rotterdam; H Ahsan; A B West; R Dubrow; J F Fraumeni; W J Blot Journal: Cancer Causes Control Date: 2000-03 Impact factor: 2.506
Authors: Linda M Liao; Thomas L Vaughan; Douglas A Corley; Michael B Cook; Alan G Casson; Farin Kamangar; Christian C Abnet; Harvey A Risch; Carol Giffen; Neal D Freedman; Wong-Ho Chow; Shahram Sadeghi; Nirmala Pandeya; David C Whiteman; Liam J Murray; Leslie Bernstein; Marilie D Gammon; Anna H Wu Journal: Gastroenterology Date: 2011-11-19 Impact factor: 22.682
Authors: Meira Epplein; Abraham M Y Nomura; Lynne R Wilkens; Brian E Henderson; Laurence N Kolonel Journal: Am J Epidemiol Date: 2009-07-07 Impact factor: 4.897
Authors: Young-Il Kim; So Young Kim; Ji Hyun Kim; Jun Ho Lee; Young-Woo Kim; Keun Won Ryu; Jong-Hyock Park; Il Ju Choi Journal: Cancer Res Treat Date: 2015-07-14 Impact factor: 4.679